Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth

BACKGROUND: Although there are reports that metronomic cyclophosphamide (CTX) can be immune stimulating, the impact of its combination with anti-CTLA-4 immunotherapy for the treatment of cancer remains to be evaluated. METHODS: Murine EMT-6/P breast cancer, or its cisplatin or CTX-resistant variants...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Parra, Karla, Valenzuela, Paloma, Lerma, Natzidielly, Gallegos, Alejandra, Reza, Luis C, Rodriguez, Georgialina, Emmenegger, Urban, Di Desidero, Teresa, Bocci, Guido, Felder, Mitchell S, Manciu, Marian, Kirken, Robert A, Francia, Giulio
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5294484/
https://ncbi.nlm.nih.gov/pubmed/28056464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.429
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars